Literature DB >> 3323595

Dynamics of erythropoiesis following renal transplantation.

A Besarab1, J Caro, B E Jarrell, G Francos, A J Erslev.   

Abstract

We examined the temporal dynamics of the correction of anemia following renal transplantation in 65 recipients using a sensitive radioimmunoassay for erythropoietin to determine the effects of modern immunosuppressive agents, delayed graft function, and early acute rejection. Pretransplant mean erythropoietin (25.6 +/- 3.3 mU/ml) was only 25% of the expected value at the mean hematocrit of 27.2 +/- 0.7, and erythropoietin correlated positively with hematocrit (r = 0.37, P less than 0.05). Following onset of graft function, erythropoietin increased to 109 +/- 13 mU/ml and then decreased in a negative feedback fashion over the next several months. Delayed graft function was associated with delay in the assumption of this orderly process irrespective of the immunosuppressive regimen used. Cyclosporine A produced a biphasic response despite delayed graft function in recipients with underlying adult polycystic kidney disease. Correction of anemia required resumption of graft function. Onset of acute graft rejection within the first month posttransplantation (14 episodes in 11 patients) abrogated the hematopoietic response until the rejection was successfully reversed. We conclude that a major cause for the anemia of renal failure is subnormal production of erythropoietin. Following transplantation, anemia corrects in an orderly manner with restoration of the normal biofeedback process between erythropoietin and red cell mass. This process is delayed by failure of graft to function initially and interrupted by acute early rejection, re-commencing following successful reversal.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3323595     DOI: 10.1038/ki.1987.241

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

1.  Post-transplant erythrocytosis refractory to ACE inhibitors and angiotensin receptor blockers.

Authors:  Prakash Vishnu; Yenny Moreno Vanegas; Hani M Wadei; Candido E Rivera
Journal:  BMJ Case Rep       Date:  2018-06-28

Review 2.  Erythropoiesis and erythropoietin levels in renal transplant recipients.

Authors:  M Wolff; W Jelkmann
Journal:  Klin Wochenschr       Date:  1991-01-22

3.  Erythropoietin in thrombotic thrombocytopenic purpura and acute renal failure.

Authors:  S Heidenreich; K H Rahn; W Zidek
Journal:  Clin Investig       Date:  1992-02

4.  Post-renal transplantation anemia at 12 months: prevalence, risk factors, and impact on clinical outcomes.

Authors:  Zhongli Huang; Turun Song; Lei Fu; Zhengsheng Rao; Dongyang Zeng; Yang Qiu; Xianding Wang; Libo Xie; Qiang Wei; Li Wang; Tao Lin
Journal:  Int Urol Nephrol       Date:  2015-08-06       Impact factor: 2.370

5.  Erythropoietin in polycystic kidneys.

Authors:  K U Eckardt; M Möllmann; R Neumann; R Brunkhorst; H U Burger; G Lonnemann; H Scholz; G Keusch; B Buchholz; U Frei
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

6.  Dosing of erythropoiesis-stimulating agents can be reduced by a new administration regimen.

Authors:  Bergur V Stefánsson; Börje Haraldsson; Ulf Nilsson
Journal:  Nephron Extra       Date:  2011-08-19

Review 7.  Understanding renal posttransplantation anemia in the pediatric population.

Authors:  Paul Joseph Galutira; Marcela Del Rio
Journal:  Pediatr Nephrol       Date:  2011-11-16       Impact factor: 3.714

8.  Interstitial fibroblasts in donor kidneys predict late posttransplant anemia.

Authors:  Aki Mafune Hamada; Izumi Yamamoto; Mayuko Kawabe; Haruki Katsumata; Takafumi Yamakawa; Ai Katsuma; Yasuyuki Nakada; Akimitsu Kobayashi; Yusuke Koike; Jun Miki; Hiroki Yamada; Takahiro Kimura; Yudo Tanno; Ichiro Ohkido; Nobuo Tsuboi; Hiroyasu Yamamoto; Mitsuyoshi Urashima; Takashi Yokoo
Journal:  Clin Kidney J       Date:  2019-09-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.